 |
종근당. (사진=종근당) |
[Alpha Biz= Kim Jisun] Seoul, September 9 – Chong Kun Dang Group Chairman Lee Jang-han and his wife, Jung Jae-jung, have transferred their entire holdings in subsidiary Kyungbo Pharmaceutical to their three children, while also acquiring an IT media outlet to bolster the Group’s digital strategy.
According to a regulatory filing on September 9, Chairman Lee and his wife gifted 479,363 and 478,140 shares of Kyungbo Pharmaceutical, respectively, to their children – Lee Joo-won, Lee Joo-kyung, and Lee Joo-ah.
Following the transfer, eldest son Lee Joo-won, an executive director at Chong Kun Dang, increased his holdings to 1,484,783 shares, raising his ownership stake to 6.21%. His sisters Lee Joo-kyung and Lee Joo-ah each received 300,000 shares, resulting in ownership stakes of 5.62% and 5.26%, respectively.
Kyungbo Pharmaceutical focuses on generics and active pharmaceutical ingredients (APIs). The company reported ₩238.6 billion in revenue in 2023, up 10.3% year-on-year, and operating profit of ₩10.5 billion, a sharp 88.5% increase.
While the company has not provided details regarding the stock transfer, industry observers note that the move could reduce tax burdens while allowing greater flexibility in succession planning. The Group also emphasized that the IT media acquisition was part of a broader effort to strengthen its digital and information strategy.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
